



JC04 Rec'd CT/PTO 01 NOV 2005
PATENT APPLICATION

#7

UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Pandurang Balwant DESHPANDE et al.

Attn: **Mail Stop Missing Parts**

Application No.: 10/532,753

Docket No.: 123561

Filed: April 27, 2005

For: NOVEL AMORPHOUS HYDRATE OF A CEPHALOSPORIN ANTIBIOTIC

**RESPONSE TO NOTIFICATION TO COMPLY –
NO SEQUENCES IN PATENT APPLICATION**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed September 1, 2005 (copy attached), the patent application contains no nucleotide and no amino acid sequences. Thus, a Sequence Listing is not required under 37 C.F.R. §1.821.

Entry of the executed Declaration of the Inventors on May 13, 2005 should have completed all of the filing formalities. Accordingly, prompt issuance of a Filing Receipt, and prompt examination and allowance of this application are respectfully solicited.

Respectfully submitted,


James A. Cliff
Registration No. 27,075

Philip A. Caramanica, Jr.
Registration No. 51,528

JAO:PAC/jam

Date: November 1, 2005

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/532,753	Pandurang Balwant Deshpande	123561
		INTERNATIONAL APPLICATION NO.
		PCT/IB03/05032
LA. FILING DATE		PRIORITY DATE
11/10/2003		11/15/2002

25944
OLIFF & BERRIDGE, PLC
P.O. BOX 19928
ALEXANDRIA, VA 22320



Date Mailed: 09/01/2005

CONFIRMATION NO. 9152
371 FORMALITIES LETTER
OC000000016902140
OC000000016902140 DUE DATE

NOV 01 2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST
- Send e-mail correspondence for Patentin Software Program Help @ ebus@uspto.gov

RECEIVED
By JWW on 9/2 2005
and
By MRI on 9/2 2005
Oliff & Berridge

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/532,753	PCT/IB03/05032	123561

FORM PCT/DO/EO/922 (371 Formalities Notice)